Efficacy and Safety of YSCH-01 by Shanghai Yuansong in Advanced Solid Tumors in Clinical Study 

To cite: He Y, Huang X, Li X, et al. Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. Journal for ImmunoTherapy of Cancer 2024;12:e008999. doi: 10.1136/jitc-2024-008999
Read the full article here: dx.doi.org/10.1136/jitc-2024-008999
Objective: To evaluate the safety and preliminary efficacy of YSCH-01 (Recombinant L-IFN adenovirus) in subjects with advanced solid tumors.
Conclusion: The study shows that YSCH-01 injections were safe and well tolerated and exhibited preliminary efficacy in patients with advanced solid tumors, supporting further investigation to evaluate its efficacy and safety.

Наука